But it’s not going to be in the new CDF? It’s not clear, but the re-appraisal has a new section “Cancer Drugs Fund reconsideration” that seems to say that further data collection is not possible. However, with one ‘plausible’ estimate of post-treatment benefits and another ‘no unreasonable’ estimate of best supportive care costs, it becomes cost-effective after a further discount from Pfizer.
Read it yourself and see what you think. It’s here.
